Market Overview

UPDATE: Piper Jaffray Cuts PT to $8 on Rigel Pharmaceuticals Following Disappointing Phase II Results

Share:
Related RIGL
Soaring +11% In Pre-Market, Rigel Receives Buy Initiation Amid Fostamatinib Phase 3 Optimism
Rigel Pharma Gets Bulls From JPMorgan Before New Phase 3 Data: What To Know

Piper Jaffray reiterated its Overweight rating on Rigel Pharmaceuticals (NASDAQ: RIGL) and increased its price target from $14 to $8.

Piper Jaffray commented, "We are maintaining our Overweight rating but cutting our price target to $8 from $14 following disappointing results from the OSKIRA-4 Phase II trial. In particular, fostamatinib's inability to achieve non-inferiority to Abbott's Humira could have negative commercial implications. As a result, we have reduced our fostamatinib revenue estimates."

Rigel Pharmaceuticals closed at $5.90 on Wednesday.

Latest Ratings for RIGL

DateFirmActionFromTo
Jul 2016H.C. WainwrightInitiates Coverage onBuy
Jun 2016Piper JaffrayInitiates Coverage onOverweight
May 2016JefferiesMaintainsBuy

View More Analyst Ratings for RIGL
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (RIGL)

View Comments and Join the Discussion!